A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 67; no. 3; pp. 325 - 329
• Main Authors: Leong, Swan Swan, Fong, Kam Weng, Lim, Wan Teck, Toh, Chee Keong, Yap, Swee Peng, Hee, Siew Wan, Tan, Eng Huat
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ireland Ltd 01.03.2010; Elsevier
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - radiotherapy; Carcinoma, Non-Small-Cell Lung - therapy; Chemo-radiotherapy; Combined Modality Therapy; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Female; Gemcitabine; Hematology, Oncology and Palliative Medicine; Humans; Locally advanced; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - radiotherapy; Lung Neoplasms - therapy; Male; Medical sciences; Middle Aged; Non-platinum; Pneumology; Pulmonary/Respiratory; Remission Induction; Tumors; Tumors of the respiratory system and mediastinum; Vinblastine - administration & dosage; Vinblastine - analogs & derivatives; Vinorelbine; Non-platinum; Chemo-radiotherapy; Gemcitabine; Lung cancer; Locally advanced; Vinorelbine; Antineoplastic agent; Lung disease; Induction; Respiratory disease; Concurrent; Malignant tumor; non-small cell lung carcinoma; Radiotherapy; Cisplatin; Chemotherapy; Cancerology; Treatment; Platinum; Phase II trial; Carboplatin; Bronchus disease; Cancer; Pneumology
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2009.04.022

Abstract This is phase II study evaluating a non-platinum-containing regimen, used in conjunction with radiotherapy, in patients with locally advanced non-small cell lung cancer (NSCLC). Patients with non-resectable stage III NSCLC were treated with two cycles of induction gemcitabine (1000 mg/m2 ) and vinorelbine (25 mg/m2 ) given on D1,8 every 21 days, followed by thoracic radiotherapy (60–66 Gy) with concurrent weekly vinorelbine (15 mg/m2 ). The primary objective was to assess response rate and secondary objectives to assess tolerability and to determine the progression-free survival (PFS) and overall survival (OS). Of the 42 patients enrolled on the study, 15 (36%) achieved a partial response (PR) after induction chemotherapy. After chemo-radiotherapy, five patients had complete response (CR) and 19 patients had PR, giving an overall response rate of 52%. The median PFS was 8 months and median OS was 17 months. The regimen was tolerable, with a 21% grade 3/4 neutropenia rate and 38% grade 2/3 esophagitis rate.